tirzepatide and osteoporosis Tirzepatide, a dual GLP-1 GIP receptor agonist, promotes bone loss in obese mice via gut microbial-related metabolites Tirzepatide, a dual GLP-1 and

While human risk remains unproven, individuals with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) shouldnt use this medication

It is derived from the C-terminal portion of alpha-melanocyte-stimulating hormone and has been studied for anti-inflammatory signaling, gut inflammation models, and immune-modulating effects

Evidence-based GLP-1 care Custom-formulated compounded medications using ingredients commonly prescribed in medical practice

a commercial product called PROFIN) in a single-center, double-blind, randomized, placebo-controlled study in 72 healthy women (4065 years of age) with moderate eye wrinkles who met the study criteria [45]

analyses and graphics were made in R 4.3.2

About CagriSema CagriSema is being investigated by Novo Nordisk as a once-weekly subcutaneous injectable treatment for adults with overweight or obesity (REDEFINE program) and as a treatment for adults with type 2 diabetes (REIMAGINE program)